Your browser doesn't support javascript.
loading
The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma.
Pal, Dhananjaya; Vann, Kendra R; Joshi, Shweta; Sahar, Namood E; Morales, Guillermo A; El-Gamal, Dalia; Kutateladze, Tatiana G; Durden, Donald L.
Affiliation
  • Pal D; Division of Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
  • Vann KR; Department of Pediatrics Computational Chemistry, College of Medicine University of Nebraska Medical Center, Omaha, NE, USA.
  • Joshi S; Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA.
  • Sahar NE; Division of Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
  • Morales GA; Division of Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
  • El-Gamal D; Department of Pediatrics Computational Chemistry, College of Medicine University of Nebraska Medical Center, Omaha, NE, USA.
  • Kutateladze TG; SignalRx Pharmaceuticals, Inc., Cumming, GA, USA.
  • Durden DL; Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
iScience ; 24(9): 102931, 2021 Sep 24.
Article in En | MEDLINE | ID: mdl-34557659
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: IScience Year: 2021 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: IScience Year: 2021 Document type: Article Affiliation country: United States Country of publication: United States